{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-315074","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.791268+00:00","generated_at":"2026-05-16T13:32:30.522977+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026","bullets":["Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.","Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.","Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.","Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.","Saha resignation not due to any disagreement with company's operations or policies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-315074","json":"https://secwatch.observer/filing/0001193125-25-315074.json","markdown":"https://secwatch.observer/filing/0001193125-25-315074.md","text":"https://secwatch.observer/filing/0001193125-25-315074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/0001193125-25-315074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/d933269d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:32:30.522977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}